Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans reveal hidden clues behind Parkinson's Non-Motor symptoms

NCT ID NCT02038608

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study used PET scans to examine brain changes in people with Parkinson's disease at different stages. Researchers looked at two brain chemical systems—dopamine and serotonin—to understand non-motor symptoms like mood and thinking problems. 49 participants, including healthy volunteers, were involved. The goal was to learn how these systems change over time, not to test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

49 people

The number who actually took part.

Start date

Dec 2014

Finished

Jul 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients * Patients presenting doparesponsive Parkinson's disease * Patient's age between 40 and 70 years old * Absence of other neurological or psychiatric disease * Absence of cognitive decline ( MATTIS \> 130) * For women of childbearing age a pregnancy test and a contraceptive method will be required * Informed consent sign Healthy subjects * subject's age between 40 and 70 years old * Absence of neurological or psychiatric disease * Absence of cognitive decline ( MATTIS \> 130) * For women of childbearing age a pregnancy test and a contraceptive method will be required * Informed consent sign Exclusion Criteria: Patients * patient's age \< 40 years old or \> 70 years old * Other neurological or psychiatric disease * Cognitive decline (MATTIS \< 130). * Having participated to a PET or SPECT study in the last 12 months * Pregnancy * Severe concomitant disease Healthy subjects * subject's age \< 40 years old or \> 70 years old * Neurological or psychiatric disease * Cognitive decline (MATTIS \< 130). * Having participated to a PET or SPECT study in the last 12 months * Pregnancy * Severe concomitant disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Disease Progression Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease

Contacts and locations

Locations

  • Hospices Civils de Lyon, Hopital Neurologique Pierre Wertheimer

    Bron, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.